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Abstract
Background: Palliative care in cancer aims at alleviating the suffering of patients. A previous study
in patients with advanced non-small-cell lung cancer showed that adenosine 5'-triphosphate (ATP)
infusions had a favourable effect on fatigue, appetite, body weight, muscle strength, functional status
and quality of life. The present study was designed 1. To evaluate whether ATP has favourable
effects in terminally ill cancer patients, 2. To evaluate whether ATP infusions may reduce family
caregiver burden and reduce the use of professional health care services, and 3. To test the
feasibility of application of ATP infusions in a home care setting.
Methods/Design: The study can be characterized as an open-labelled randomized controlled trial
with two parallel groups. The intervention group received usual palliative care, two visits by an
experienced dietician for advice, and regular ATP infusions over a period of 8 weeks. The control
group received palliative care as usual and dietetic advice, but no ATP. This paper gives a
description of the study design, selection of patients, interventions and outcome measures.
Discussion:  From April 2002 through October 2006, a total of 100 patients have been
randomized. Follow-up of patients will be completed in December 2006. At the time of writing, five
patients are still in follow up. Of the 95 patients who have completed the study, 69 (73%) have
completed four weeks of follow-up, and 53 (56%) have completed the full eight-week study period.
The first results are expected in 2007.
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Background
The World Health Organisation noted that 'the ultimate
goal of palliative care is the achievement of the best qual-
ity of life for patients and their families' [1]. Complaints
like progressive fatigue, deterioration in performance sta-
tus, weight loss and reduced functional abilities have a
substantial impact on the quality of life, and also lead to
frequent and intensive use of professional health care
services [2,3]. It is therefore important to develop thera-
pies that contribute to the alleviation of these complaints
in terminally ill patients.
Adenosine 5'-triphosphate (ATP) is a naturally occurring
purine nucleotide which is present in every cell of the
human body, well-known because of its intracellular
energy-transferring role [4]. Furthermore, extracellular
ATP is involved in the regulation of a variety of biological
processes such as neurotransmission, muscle contraction,
cardiac function, platelet function, vasodilatation, and
liver glucose metabolism [4]. A previous randomized clin-
ical trial in 58 patients with advanced non-small-cell lung
cancer (NSCLC) showed that 10 intravenous 30-hour ATP
infusions every 2 to 4 weeks in a clinical setting had a
favourable effect on fatigue, appetite, body weight, muscle
strength, functional status and quality of life [5]. Side
effects (mainly chest discomfort, dyspnea and urge to take
a deep breath) observed during ATP infusion were mild
and disappeared rapidly after lowering the infusion rate
[6].
Considering the relatively mild character of ATP therapy,
application of ATP infusions in palliative home care
might be a promising and relatively simple treatment to
improve the quality of life and functional status of
patients with advanced cancer. Based on this considera-
tion, we initiated a study in terminally ill cancer patients,
aiming:
1. To evaluate whether ATP has favourable effects in termi-
nally ill cancer patients,
2. To evaluate whether ATP infusions may reduce family
caregiver burden and reduce the use of professional health
care services, and
3. To test the feasibility of application of ATP infusions in
a home care setting.
In the present paper, we describe the design, selection of
patients, intervention and outcome measures of this
study.
Methods/Design
Study design and general outline
Figure 1 displays the outline of the study design. The study
can be characterized as an open-labelled randomized con-
trolled trial with two parallel groups. Patients eligible for
the study were, after stratification, randomly allocated to
the intervention or control group. The intervention group
received palliative care as usual and two visits by an expe-
rienced dietician for advice, and regular ATP infusions
over a period of 8 weeks. The control group received pal-
liative care as usual and dietetic advice, but no ATP. Pri-
mary and secondary outcomes were assessed at baseline
and every two weeks thereafter, until eight weeks after ran-
domization. To minimize patient burden, all outcome
measurements were taken at the patients' home. Part of
the data were collected with assistance from the patients'
partner or family caregiver (e.g. dietary record, medica-
tion, use of professional care services). The study was
approved by the Ethical Committee of the University Hos-
pital Maastricht and Maastricht University.
Study population
Eligible were patients with cytologically or histologically
confirmed cancer, for whom medical treatment options
were restricted to supportive care, who had a life expect-
ancy < 6 months, had a World Health Organization
(WHO) performance status 1 or 2, and suffered from at
least one of the following complaints: fatigue, weight loss
> 5% over the last 6 months, or anorexia. Patients with a
WHO performance status > 2 were excluded because they
were not able to attend the clinic and to undergo antropo-
metric and muscle strength measurements. Furthermore,
patients with symptomatic angina pectoris, symptomatic
heart failure or any form of atrioventricular (AV) block
(assessed by electrocardiogram) were excluded for safety
reasons [7,8]. Other exclusion criteria were: life expect-
ancy < 4 weeks, concurrent palliative chemotherapy, cog-
nitive dysfunction, and other diseases hampering
adequate follow up. The eligibility of patients was evalu-
ated by a medical oncologist before inclusion. Written
informed consent was obtained from all patients.
Patient recruitment
Patients were recruited through the Departments of Med-
ical Oncology and Pulmonology of five hospitals in differ-
ent regions in the Netherlands (Maastricht, Heerlen,
Eindhoven and Utrecht). When the last line of chemo-
therapy had failed and medical treatment options were
restricted to supportive care, the patient was informed
about the study by the oncologist or pulmonologist. In
addition, general practitioners in the region of Maastricht
participated in patient recruitment.BMC Public Health 2007, 7:4 http://www.biomedcentral.com/1471-2458/7/4
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Study design Figure 1
Study design.
Study population
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Randomisation
After baseline measurements, patients were randomly
allocated to the treatment group, using random numbers
generated by computer with a permuted block size of four.
Before randomization participants were stratified for
tumor type (colon cancer, breast cancer, and other types
of cancer) and weight loss (≤ 5% in 6 months vs. > 5%),
since weight loss is an important prognostic factor for
deterioration of physical condition and quality of life [9].
Intervention
General
Patients in both the experimental and control group
received care as usual, i.e. patients were allowed to use and
apply for all available health care services. As an addi-
tional support for patients both in the intervention and
control group, all patients were visited at home by an
experienced dietician in week 2 and 6 of the study. At
these visits, using a standard checklist, problems and com-
plaints were noted and followed by standard nutritional
advice based on the type of complaints of the patient. For
this purpose, information sheets were designed contain-
ing a standard nutritional advice for any of the following
complaints: weight loss, anorexia, food aversions, nausea
and vomiting, swallowing problems, dry mouth, painful
mouth, diarrhoea, and obstipation. In case patients asked
for more intensive dietary support or for specific nutri-
tional supplements, they were referred to a regular dieti-
cian in hospital or home care.
ATP
Patients allocated to the experimental study group
received weekly ATP infusions over a period of eight
weeks. A longer infusion period was not considered feasi-
ble in these patients because of the expected rapidly dete-
riorating condition of participating patients.
In our previous study in NSCLC patients, 10 intravenous
30-hour ATP infusions were given at 2 to 4-week intervals
[5]. Because of the advanced disease stage in the present
study, a less intensive treatment schedule of 10 hours
(range 8 – 12 hours) was chosen, in order to avoid ATP
administration during the night or an overnight stay at the
hospital. To increase the overall ATP dose given, ATP was
administered on a weekly basis. A dose of 50 mcg/kg.min,
or lower when side effects occurred, was chosen in order
to maximize safety at home; in our previous study a large
proportion of patients did not tolerate the dose of 75
mcg/kg.min. ATP infusions were started beginning at a
dose of 20 mcg/kg.min, and were increased in steps of 10
mcg/kg.min every 10 minutes until a maximum dose of
50 mcg/kg.min, or until the maximally tolerated dose, if
this was lower, had been reached. Thereafter, ATP was
infused at a continuous rate. If any side effects occurred,
the dose was reduced until side effects disappeared.
In the previous study ATP infusions were given in a clini-
cal setting under strict medical supervision. Since patients
in the present study were in a considerably later stage of
disease, with consequently a shorter life expectancy, the
majority of patients was supported by the general practi-
tioner and were discharged from routine specialist care,
with only occasional visits to the out-patient clinic, when
necessary. For this reason, it was decided to basically
administer most of the ATP infusions in the home setting.
However, since initiation of ATP infusions under medical
supervision in a clinical setting would facilitate the treat-
ment of possible side effects, the first two ATP infusions
were given at the day care center of the participating hos-
pitals. Based on the mild character of the noted side effects
during the first two infusions in the first 22 patients, an
amendment was granted by the Ethical Committee during
the study for administering only the first ATP infusion at
the day care center, and all subsequent infusions at home.
At the end of the first infusion, the safety and tolerated
dose of ATP was evaluated for each individual patient.
Subsequent infusions were given at the patients' home by
an experienced and trained nurse of the infusion team of
the Community Care Organization. The maximally toler-
ated dose during the first infusion at the day care center
was also the maximum dose for the next infusions at
home. At home, ATP infusions also started with a dose of
20 mcg/kg.min and increased in steps of 10 mcg/kg.min
every 10 minutes until the maximum tolerated dose had
been reached. To provide maximal mobility a portable
infusion pump was used during ATP administration.
Patients and their partners were instructed extensively
regarding the infusion procedures and to call the infusion
team of the Community Health Care Organisation in case
of side effects or other problems, such as technical prob-
lems.
Side effects and adverse events
Side effects of all ATP infusions, adjustments of dosage
schedules, and any other problems occurring during the
infusions were registered systematically on a standard
form by the medical and nursing staff of the day care
center of the participating hospitals, the nurses of the
home infusion teams and the researcher according to
WHO Common Toxity Criteria [10].
Any adverse event that occurred from baseline until one
week after the last ATP infusion was reported by the inves-
tigator on the appropiate Case Report Form. Patients and
their caregivers were instructed to contact the investigator
if an adverse event occurred. All serious adverse events
that were unexpected and assessed to be related to the
study product were to be reported to the principal investi-
gator of the study within 24 hours.BMC Public Health 2007, 7:4 http://www.biomedcentral.com/1471-2458/7/4
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Outcome assessment
Most of the outcome measures were adapted from the
study from Agteresch et al [5].
Primary outcome measures
Primary outcome measures were quality of life, fatigue and
physical restriction (see Table 1).
Quality of life was assessed using the EORTC Quality of
Life Questionnaire (QLQ-C30, version 3.0) [11,12]. The
QLQ-C30 is a 30-item cancer-specific core questionnaire
that addresses various domains of QoL. It contains five
functional scales (physical functioning, role functioning,
emotional functioning, cognitive functioning and social
functioning), three symptom scales (fatigue, pain and
nausea/vomiting), two items assessing global health and
quality of life, and a number of single items addressing
various symptoms (constipation, diarrhoea, dyspnea,
anorexia and insomnia) and perceived financial impact.
All items are scored on a 4-point Likert-type scale. The
content areas covered by this questionnaire reflect the
multi-dimensionality of the quality of life construct. The
EORTC QLQ has been extensively used for assessing
health-related quality of life in patients with a wide range
of cancers. Studies in patients with advanced cancer with
a short life expectancy showed that the questionnaire was
well accepted, with a high completion rate and useful in
detecting the effectiveness of palliative treatment over
time. Results confirmed that the QLQ-C-30 is a reliable
and valid measure of the quality of life in patients with
advanced cancer [13,14].
In addition to the QLQ-C30, we used the overall question
from the Rotterdam Symptom Checklist ("overall, how
did you feel over the past week") as a general indicator of
perceived QoL. The Rotterdam Symptom Checklist was
originally validated in a Dutch study [15] and has since
then been used in numerous studies in cancer patients.
Fatigue was measured by the Short Fatigue Questionnaire
(SFQ). The SFQ is a reliable and simple instrument to
assess bodily fatigue [16]. The questionnaire comprises 4
items. Each item is scored on a 7-point Likert scale.
Physical restriction was assessed by the Groningen Activity
Restraint Scale (GARS-4) [17]. The GARS-4 was developed
to assess disability in the domains of personal care (11
items) and domestic activities (7 items). Studies in per-
sons receiving home care, healthy seniors, patients with
recent diagnosed cancer, multiple sclerosis, or rheuma-
toid arthritis showed that the GARS is an easy to adminis-
ter, reliable, and valid measure for assessing disability in
the domains of ADL (Activities of Daily Living) and IADL
(Instrumental Activities of Daily Living) [18,19].
Secondary outcome measures
Secondary outcome measures were:
- Appetite, assessed by four 100 mm visual analogue scales
(VAS) related to hunger and satiety with words anchored
at each end expressing the most positive or negative sen-
sation. Some studies have investigated the correlation
between hunger ratings and energy intake, i.e. the validity
of the appetite ratings. Many of these have failed to dem-
Table 1: Time schedule of outcome assessment
Outcome measure Measurement scale or specification Timing (in weeks)
Primary outcomes 02468
Quality of Life EORTC QLQ-C30* X X X
Q u a l i t y  o f  L i f e R S C L ,  o v e r a l l  q u e s t i o n  * * XXXXX
F a t i g u e S F Q * * * XXXXX
P h y s i c a l  r e s t r i c t i o n G A R S - 4 * * * * XXXXX
Secundary outcomes
Appetite Appetite Questionnaire X X X
Nutritional intake 3-Day food diary X X X
M e d i c a t i o n M e d i c a t i o n  l i s t XXXXX
B o d y  w e i g h t E l e c t r o n i c  w e i g h i n g  s c a l e XXXXX
Triceps skinfold XXXXX
Arm circumference XXXXX
Muscle strength Biceps and quadriceps strength X X X
M u s c l e  s t r e n g t h H a n d g r i p  s t r e n g t h XXXXX
Use of professional care services Diary and health care registration XXXXX
* European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30
** Rotterdam Symptom Checklist, overall question ("overall, how did you feel over the past week")
*** Short Fatigue Questionnaire
**** Groningen Activity Restriction ScaleBMC Public Health 2007, 7:4 http://www.biomedcentral.com/1471-2458/7/4
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onstrate such a relationship, while others have found that
there was an association [20,21]. Results obtained from
VAS yield the most valuable information when combined
with other aspects of energy balance [22].
- Nutritional intake was assessed by a 3-day food diary.
Patients were taught to keep records, in portion sizes, of
all the foods they had eaten on several days of the study.
The portion sizes were described in household measures
using the utensils commonly found in their homes. These
household measures were quantified by volume by the
investigator. In general, a 3-day record, randomized to
cover seasonal and weekday variations is recommended
to assess mean food consumption of a group of individu-
als [23]. A review about the validity of self-reported energy
intake showed that energy intake derived from all meth-
ods of food recording can be an imprecise measure that is
substantially under-reporting in groups including adults,
children and adolescents, obese persons, athletes, military
personnel and trekking explorers [24]. No data about
patients with cancer are available.
- Medication; changes were registered during each home
visit.
- Body height, measured to the nearest 0.1 centimeter.
- Body weight was measured without shoes, using an elec-
tronic weighing scale (Soehnle 7407 Translucia, Ger-
many) to the nearest 0.05 kg.
- Triceps skin fold thickness was measured in duplicate with
a Holtain® skinfold caliper (CMS weighing equipment
LTD, London UK) to calculate total body fat mass (FM)
using the age- and gender-specific tables from Durnin and
Womersley [25]. Fat-free mass (FFM) was calculated by
subtracting fat mass from body weight.
- Mid-upper arm circumference of the dominant arm was
measured with a flexible measuring tape, and arm muscle
area derived using the equation: (arm circumference - π ×
triceps skinfold)2/4 π [26]. Arm muscle area gives an indi-
cation of the body's muscle mass as its main protein
reserve [26].
- Muscle strength of two major muscle groups (i.e. elbow
flexor and knee extensor muscles) were assessed at the
dominant arm and leg using a hand/held Microfet2®
dynamometer (Biometrics Europe BV, Almere, The Neth-
erlands). This technique has been validated in several
patient groups, mostly in patients whit limited muscle
strength [27-29]. The patient while sitting exerts a maxi-
mal force with the 90° flexed elbow, while the examiner
pushes with the dynamometer against the patients' thumb
pad until muscle strength is overcome (break test). Simi-
larly, the patient exerts a maximal force with the 90°
flexed knee, while the examiner pushes with the
dynamometer against the patients' ankle until muscle
strength is overcome. The strength of both muscle groups
is measured twice at an interval of approximately one
minute. Muscle strength is expressed in Newtonmeter
(Nm) units and calculated by dividing the measured
mean strength (dynamometer reading) by the distance
from dynamometer position point to the medial humeral
epicondylus medialis (elbow) and the medial femoral
epicondylus medialis (knee).
Handgrip strength of the dominant hand was measured
using a JAMAR hydraulic hand dynamometer (Saehan
Corp. Masan, Korea). Handgrip strength is a simple,
quick, easily performed, and readily available bedside test.
Studies in several population groups showed strong posi-
tive correlations between handgrip strength and lean
body mass [30]. Furthermore, handgrip strength is corre-
lated with total body muscle strength [31].
In order to exclude inter-observer variability, longitudinal
anthropometric and muscle strength measurements in
each patient were performed by the same observer.
Caregiver burden
The second study objective was to evaluate whether ATP
infusions could relieve family caregiver burden and
reduce the use of professional health care services. Car-
egiver burden was measured at two levels: 1. informal
care; 2. professional care. To measure caregiver burden we
used the GARS-4. For each item it must be marked
whether the patient, the family caregivers or health care
professionals carried out the activities (not at all, partly,
completely). Use of medical care services (hospital admis-
sions, outpatient clinic visits, general practitioner con-
tacts), and home care (both domestic and nursing care)
was recorded every visit.
Process evaluation
The evaluation of feasibility of the ATP infusions was per-
formed by open interviews with the staff of the day care
center and the nurses of the infusion home teams after fin-
ishing patient recruitment. Aspects such as procedures
concerning the transfer of ATP infusions from hospital to
home, the responsibility of the general practitioner for the
administration of home infusions and the technical and
logistical bottlenecks were particularly evaluated. Further-
more, information about patient satisfaction regarding
the safety and the burden of the ATP infusions was col-
lected during each follow-up visit by one standard ques-
tionnaire for the patient and a second for his/her partner.BMC Public Health 2007, 7:4 http://www.biomedcentral.com/1471-2458/7/4
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Data management and statistical analysis
Data were entered using Microsoft Access 2000 and
checked for errors by double data entry.
Comparability of baseline characteristics among the ATP
and control group were assessed for age, gender, tumor
type, performance status and weight loss by descriptive
statistics (SPSS). Differences over time in the two groups
were analyzed according to the 'intention-to-treat' princi-
ple by repeated-measures analysis of covariance with the
use of the linear regression model. These analyses were
performed with the SAS procedure Proc Mixed, with the
use of the independence working correlation structure.
Multivariate analyses were used to adjust the estimated
effects for potential confounders.
Sample size/power calculation
Data from a previous study in NSCLC patients [5] (related
to 8 weeks of follow-up) were used to calculate the sample
size needed to detect clinically relevant effects of ATP infu-
sion on the primary outcome measures fatigue and phys-
ical restriction. For both measures we assumed a mean
deterioration in the control group similar to the one
observed in the previous study. In the experimental group,
based on an expected worse condition of patients in the
present study when compared with our previous study in
NSCLC patients, we used a conservative estimate. Based
on our previous randomized trial with ATP infusions [5],
it was calculated that a total of 60 patients would be suffi-
cient to detect a between-group difference of 0.65 units in
fatigue on a 4-point scale after 8 weeks with a power of
90% and a two-tailed alpha of 0.05. An uncertain factor in
sample size calculation was the drop-out rate which was
estimated to vary from 25–40%. Assuming a drop-out rate
of 25% during the 8-week follow-up period, a total of 80
patients (40 patients per treatment arm) would be
needed; in case of higher drop out (e.g. 40%) recruitment
would be increased to 100 patients.
Discussion
From April 2002 through October 2006, a total of 100
patients have been randomized: 10 patients in 2002, 5 in
2003, 22 in 2004, 40 in 2005, and 23 in 2006. The study
was closed on October 31 2006. Follow-up of patients
will be completed in December 2006. At the time of writ-
ing, five patients are still in follow up. Of the 95 patients
who have completed the study, 69 (73%) have completed
four weeks of follow-up, and 53 (56%) have completed
the full eight-week study period.
We hope this study will demonstrate that ATP infusions
leads to a reduction of frequently reported complaints in
terminally ill cancer patients, for which no effective treat-
ment is yet available. In addition, we hope to show that
ATP-infusions can be administered safely in a home care
setting. In case of positive findings, this trial may be a first
step towards implementation of ATP infusions in inte-
grated palliative care. The first results are expected in
2007.
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